Skip to main content
NewslettersWatchlist

Fireman B.V.(IFRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.3993
Day High1.4900
Open:1.4200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
Barchart
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes
Motley Fool
Why InflaRx Stock Skyrocketed This Week
Motley Fool
Why Shares of InflaRx Are Soaring Wednesday
Barchart
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment
Globe Newswire
InflaRx Reports Second Quarter 2022 Financial & Operating Results
Globe Newswire
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
Globe Newswire
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
Globe Newswire
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Globe Newswire
InflaRx to Present at the H.C. Wainwright Global Investment Conference
Globe Newswire
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
Globe Newswire
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Globe Newswire
InflaRx Reports Full Year 2021 Financial and Operating Results
Globe Newswire
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
Globe Newswire
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
Globe Newswire
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
Globe Newswire
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
Globe Newswire
InflaRx to Present at Annual SVB Leerink Global Health Conference
Globe Newswire
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
Globe Newswire
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
Globe Newswire
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
Globe Newswire
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
Globe Newswire
InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference
Globe Newswire
InflaRx Reports Third Quarter 2021 Financial & Operating Results
Globe Newswire
InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference
Globe Newswire
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
Globe NewsWire
InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
Globe NewsWire
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
Globe NewsWire
InflaRx to Present at the BTIG Virtual Biotechnology Conference
Globe NewsWire
InflaRx Reports Second Quarter 2021 Financial & Operating Results
Globe NewsWire
InflaRx to Present at the Raymond James Human Health Innovation Conference

Profile

InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.